Figure 6.

Bim suppresses TH/TR-enhanced doxorubicin resistance and metastasis. (a) In the presence of cisplatin (2.5 μg/ml) and doxorubicin (2.5 μM), the migratory and (b) invasive properties of J7-TR cells treated with or without T₃ were assessed using the transwell assay. Images of traversing cells are shown in the left panels and the quantitative results in the right panels. To assess the influence of Bim on chemotherapeutic drugs-mediated invasion of J7-TR cells, (c) invasive properties of control or Bim-overexpressing J7-TR cells were stimulated with cisplatin or doxorubicin in the absence or presence of T₃ and subsequently assessed using the transwell assay. Images of traversing cells are shown in the upper panels and the quantitative results in the lower panels. Differences between data were evaluated using Student's t-test (**P<0.01; *P<0.05). (d) Tumors dissected from mice were subjected to subcutaneous injection with Luc-GFP-expressing J7-Neo and J7-TR cells were introduced orthotopically into the livers of nude mice and monitored weekly with IVIS. After 4 weeks, mice were treated with vehicle or doxorubicin (10 mg/kg, once a week). Relative intensity of luminescence from IVIS is shown in the upper panel, and representative IVIS images 13 weeks after tumor inoculation are shown in the lower panels